Skip to content

Clinical trials

Breast Neoplasms trials in Singapore

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Breast Neoplasms Country / region: Singapore Clear all

184 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20031
20044
20054
20065
20078
20086
20097
20109
20115
20127
20138
201411
201511
20165
201710
20185
20198
20208
20218
202212
202312
20247
202514
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed72
Unknown status40
Recruiting28
Active, not recruiting24
Terminated11
Enrolling by invitation3
Approved for marketing3
Not yet recruiting2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National University Hospital, Singapore47
Novartis Pharmaceuticals20
Hoffmann-La Roche13
National Cancer Centre, Singapore11
AstraZeneca9
Eli Lilly and Company8
National University of Singapore7
Genentech, Inc.5
GlaxoSmithKline4
KK Women's and Children's Hospital4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Neoplasms184
Neoplasm Metastasis17
Neoplasms11
Carcinoma, Non-Small-Cell Lung10
Triple Negative Breast Neoplasms10
Colorectal Neoplasms6
Prostatic Neoplasms6
Endometrial Neoplasms5
Ovarian Neoplasms5
Colonic Neoplasms4

Trials

Showing 1 to 25 of 184. Each trial links to its page on Pharma Observatory.

84 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.